654MO High dimensional immuno-phenotyping of immunotherapy response in head and neck cancer

Abstract

Immunotherapies, in particular immune check point inhibitors (ICI), have proven to be game changing treatments of mucosal head and neck squamous cell cancer (HNSCC). Emerging successes with anti-PD-1/PD-L1 ICI therapy have lead to durable responses and prolonged survival in human papillomavirus positive (HPV+) and negative (HPV-) patients, and there is now an urgent need for predictive biomarkers to guide patient selection for highly targeted ICI therapies. There are currently no means by which to determine whether a patient would respond to anti PD-1/PD-L1 immunotherapy.